Sarepta Therapeutics, Inc. 13D and 13G filings for Arrowhead Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-15 5:28 pm Sale | 2025-08-13 | 13D | Arrowhead Pharmaceuticals, Inc. ARWR | Sarepta Therapeutics Inc. SRPT | 0 0.000% | -11,926,301 (Position Closed) | Filing |
| 2025-02-14 5:23 pm Purchase | 2025-02-07 | 13D | Arrowhead Pharmaceuticals, Inc. ARWR | Sarepta Therapeutics Inc. SRPT | 11,926,301 9.500% | 11,926,301 (New Position) | Filing |